57 281

Cited 4 times in

Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus.

Authors
Hwang, HS; Hyoung, BJ; Kim, S; Oh, HY; Kim, YS; Kim, JK; Kim, YH; Kim, YL; Kim, CD; Shin, GT; Yang, CW
Citation
Journal of Korean medical science, 25(12):1759-1765, 2010
Journal Title
Journal of Korean medical science
ISSN
1011-89341598-6357
Abstract
It is reported that a conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) relieves gastrointestinal (GI) symptom burden and improves health-related quality of life (HRQoL). However, it is unclear whether renal transplant recipients using tacrolimus receive the same benefit from the conversion. In this prospective, multi-center, open-label trial, patients were categorized into two groups by their GI symptom screening. Equimolar EC-MPS (n=175) was prescribed for patients with GI burdens; those with no complaints remained on MMF (n=83). Gastrointestinal Symptom Rating Scale (GSRS) and Gastrointestinal Quality of Life Index (GIQLI) were evaluated at baseline and after one month. Patients and physicians completed Overall Treatment Effect (OTE) at one month. EC-MPS-converted patients had worse GSRS and GIQLI scores at baseline than MMF-continued patients (all P<0.001). Significant improvements in GSRS and GIQLI scores were observed for EC-MPS-converted patients at one month, but MMF-continued patients showed worsened GSRS scores (all P<0.05). OTE scale indicated that EC-MPS patients improved in overall GI symptoms and HRQoL more than MMF patients did (P<0.001). In tacrolimus-treated renal transplant recipients with GI burdens, a conversion from MMF to EC-MPS improves GI-related symptoms and HRQoL.
MeSH terms
AdolescentAdultAgedFemaleGastrointestinal Diseases/*chemically inducedGraft Rejection/drug therapyHumansImmunosuppressive Agents/administration & dosage/*adverse effects/therapeutic useKidney Failure, Chronic/therapy*Kidney TransplantationMaleMiddle AgedMycophenolic Acid/administration & dosage/*adverse effects/*analogs &Quality of LifeQuestionnairesTablets, Enteric-CoatedTacrolimus/therapeutic use
DOI
10.3346/jkms.2010.25.12.1759
PMID
21165291
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Nephrology
AJOU Authors
신규태
Full Text Link
Files in This Item:
jkms-25-1759-1765.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse